# Government Gazette Staatskoerant

Vol. 543

Pretoria, 28 September 2010

No. 33591

### IMPORTANT NOTICE

The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's responsibility to phone and confirm that the documents were received in good order.

Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients.

## **CONTENTS · INHOUD**

No.

Page Gazette

### **GOVERNMENT NOTICE**

## Health, Department of

Government Notice

33591

# GOVERNMENT NOTICE

### DEPARTMENT OF HEALTH

No. 863

28 September 2010

# NATIONAL DEPARTMENT OF HEALTH MEDICINES AND RELATED SUBSTANCES ACT (101 OF 1965) REVIEW OF THE EXEMPTION OF VETERINARY MEDICINES FROM SECTION 18A AND 22G OF THE ACT

The Minister of Health intends to review the exemption of veterinary medicines from section 18 A and section 22G of the Medicines and Related Substances Act (101 of 1965).

Interested persons should submit substantiated comments on this publication. Comments should address the following:

- 1. Competitive pricing in the veterinary medicines market;
- 2. Categories of buyers of veterinary medicines;
- 3. Is exemption of veterinary medicines from section 18A necessary;
- 4. Is exemption of veterinary medicines from section 22G necessary;
- 5. Bonus system; rebate system or any other incentive scheme mean the payment of:
  - (a) unacceptable advertising fees;
  - (b) unacceptable credit payments;
  - (c) unacceptable data fees;
  - (d) discounts;
  - (e) formulary listing payments;
  - (f) kickbacks and perverse incentives;
  - (g) loyalty fees or similar fees or prizes or rewards;
  - (h) unacceptable marketing fees and/or co-marketing fees;
  - (i) shelf space fees;
  - (j) directors' fees, honoraria and similar compensation paid to a healthcare professional or any person who is in a position to potentially influence

4 No. 33591

medicine choice, where such professional or other person actually do not perform any services or work for which s/he is purportedly being remunerated; and/or

(k) fees, enrichment of or benefit provided to a healthcare professional, administrative staff or any business enterprise or healthcare establishment in the healthcare sector which fee, enrichment or benefit is provided on the understanding that the health establishment or professional will give preference to, or encourage the purchase, sale, prescription, dispensing, use or recommendation of a particular medicine or medicines in return for such fee, enrichment or benefit.

Comments should be submitted in writing, on a compact disc and hard copy, on the proposed review within three months of publication of this notice to:

The Director-General: Health (Attention Director: Pharmaceutical Economic Evaluations)

Private Bag X828

**PRETORIA** 

0004

DR'A MOTSOALEDI, MP

MINISTER OF HEALTH

**DATE:** 17/8/2010